Efficacy and Safety Assessment for a New UV-protected Pump Infusion Line in Intravenous Infusion Therapy
- Conditions
- Subarachnoid Hemorrhage
- Interventions
- Device: Nimodipine pump infusion
- Registration Number
- NCT04309708
- Lead Sponsor
- B. Braun Medical International Trading Company Ltd.
- Brief Summary
To verify the efficacy and safety of Original Perfusor Line (Art.No.8723017) in infusion therapy in Patients with light sensitive drug infusion.
Subjects who choose to use Original Perfusor Line for their planned infusion treatment (nimodipine injection) as per the study protocol will be enrolled. The 300 subjects will be 1:1 randomized into the experimental group or the control group, using Original Perfusor Line (Art.No. 8723017) connected with an injection pump for infusion treatment with nimodipine injection or Original Perfusor Line (Art.No.8723010) connected with an injection pump for infusion treatment with nimodipine injection, respectively.Use of both the test product and the control product will be in strict accordance with their package insert.
The primary endpoint is the percentage of products which successful infuse fluids or medications into patient's circulatory system without leakage of fluids or medications, visible catheter embolism, air embolism and micro embolism in the infusion system and the secondary endpoint is the quality assessment for the clinical application of the products,such as the percentage of products which are qualified for infusion administration including link and removal, transparence, and tenacity.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 300
- Aged ≥18 years, all genders;
- Patients who will be treated plan to use injection pump for infusion treatment with nimodipine injection by infusion pump.
- Participated in this study voluntarily and signed informed consent form.
- Patients have contraindication on Nimodipine.
- Patients allergic to polyethylene (PE) material;
- Patients with aspartate transaminase(AST) and alanine transaminase(ALT) are 2 times higher than normal range, Serum creatinine(Scr) is 1.5 times higher than normal range.
- Patient with malignant tumor, pregnant or Lactation;
- Patients had participated in other clinical trials within 1 month and in parallel with other trials;
- Patients are unsuitable to participate in this study as judged by the investigator.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Original Perfusor Line(Art.No.8723017) Nimodipine pump infusion - Original Perfusor Line(Art.No.8723010) Nimodipine pump infusion -
- Primary Outcome Measures
Name Time Method Infusion success rate 2 hours after infusion therapy completion The percentage of products which successful infuse fluids or medications into patient's circulatory system without leakage of fluids or medications
- Secondary Outcome Measures
Name Time Method Product pass rate 2 hours after infusion therapy completion percentage of the quantity of products that pass the evaluation in the sum of products that pass the evaluation and products that fail the evaluation.
Trial Locations
- Locations (5)
Beijing Tiantan Hospital, Capital Medical University
🇨🇳Beijing, Beijing, China
Sanbo Brain Hospital, Captial Medical University
🇨🇳Beijing, Beijing, China
The Second Hospital of Hebei Medical University
🇨🇳Shijiazhuang, Hebei, China
Tianjin Medical University General Hospital
🇨🇳Tianjin, Tianjin, China
Xuanwu Hospital, Capital Medical University
🇨🇳Beijing, Beijing, China